Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its experimental CAR T cell therapy for autoimmune diseases, as the company …
Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates Read More